Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Derm.MT is a Singapore-based biotechnology company specializing in advanced transdermal drug delivery systems for dermatological applications. Spun off from Nanyang Technological University (NTU), the company utilizes a proprietary dissolvable microneedle platform designed to deliver therapeutic agents directly into the skin's deeper layers. Their primary focus is on treating hair loss conditions, such as androgenetic alopecia, by enhancing the localized delivery of drugs like minoxidil. By bypassing the stratum corneum barrier painlessly, Derm.MT aims to improve treatment efficacy while minimizing systemic side effects compared to traditional topical or oral therapies. The company is also exploring applications in skin pigmentation and acne management.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Derm.MT.